Identification

Name
Vincristine
Accession Number
DB00541  (APRD00495)
Type
Small Molecule
Groups
Approved, Investigational
Description

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Structure
Thumb
Synonyms
  • 22-Oxovincaleukoblastin
  • 22-Oxovincaleukoblastine
  • Leurocristine
  • Vincristin
  • Vincristina
  • Vincristinum
External IDs
L 37231 / NSC 67574 / VCR
Product Ingredients
IngredientUNIICASInChI Key
Vincristine SulfateT5IRO3534A2068-78-2AQTQHPDCURKLKT-VEGNXYBXSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MarqiboKitTalon Therapeutics, Inc.2013-01-14Not applicableUs
Oncovin Solution 1mg/mlLiquid1 mgIntravenousEli Lilly & Co. Ltd.1984-12-311998-08-04Canada
Vincristine Sulfate Inj 1mg/ml USPLiquid1 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1989-12-311999-08-10Canada
Vincristine Sulfate Inj 5mg/vial USPPowder, for solution5 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1989-12-311996-09-10Canada
Vincristine Sulfate InjectionSolution1 mgIntravenousTeva1995-12-31Not applicableCanada
Vincristine Sulfate InjectionSolution1 mgIntravenousAccord Healthcare LimitedNot applicableNot applicableCanada
Vincristine Sulfate Injection USPSolution1 mgIntravenousUman PharmaNot applicableNot applicableCanada
Vincristine Sulfate Injection USPSolution1 mgIntravenousPfizer1997-08-07Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vincasar PFSInjection, solution1 mg/mLIntravenousTeva Parenteral Medicines, Inc.2000-05-01Not applicableUs
Vincasar PFSInjection, solution1 mg/mLIntravenousTeva Parenteral Medicines, Inc.2000-05-01Not applicableUs
VinCRIStine SulfateInjection, solution1 mg/mLIntravenousHospira, Inc.1988-04-19Not applicableUs
International/Other Brands
Alcavixin (Korea United Pharma) / Alcrist (Alkem) / Citomid (CSC) / Cytocristin (Cipla) / Oncocristin (Sun) / Oncovin (Lilly) / Oncrivin (Teva) / Sindovin (Actavis) / Tevacristin (Teva) / Vinces (Ivax) / Vincrisin (Teva) / Vincristin (Gedeon Richter) / Vincrisul (STADA) / Vinlon (Celon) / Vinracine (Meizler)
Categories
UNII
5J49Q6B70F
CAS number
57-22-7
Weight
Average: 824.9576
Monoisotopic: 824.399644032
Chemical Formula
C46H56N4O10
InChI Key
OGWKCGZFUXNPDA-XQKSVPLYSA-N
InChI
InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
IUPAC Name
methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0⁴,¹².0⁵,¹⁰]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,13-tetraene-10-carboxylate
SMILES
[H][[email protected]@]12N3CC[[email protected]@]11C4=CC(=C(OC)C=C4N(C=O)[[email protected]@]1([H])[[email protected]](O)([[email protected]](OC(C)=O)[[email protected]]2(CC)C=CC3)C(=O)OC)[[email protected]]1(C[[email protected]]2([H])CN(C[[email protected]](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC

Pharmacology

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Structured Indications
Not Available
Pharmacodynamics

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Mechanism of action

The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.

TargetActionsOrganism
ATubulin beta chain
inhibitor
Human
UTubulin alpha-4A chain
inhibitor
Human
Absorption
Not Available
Volume of distribution

Within 15 to 30 minutes after injection, over 90% of the drug is distributed from the blood into tissue, where it remains tightly, but not irreversibly, bound.

Protein binding

~75%

Metabolism

Hepatic. Cytochrome P450 isoenzymes of the CYP3A subfamily facilitate the metabolism of vincristine.

Route of elimination

The liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine.

Half life

When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.

Clearance
Not Available
Toxicity

IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg. Marqibo® must only be administered IV because it is fatal if administered by other routes. Marqibo® also has different dosing than vincristine sulphate injection, so attention is needed to prevent overdoses. The most clinically significant adverse effect of vincristine is neurotoxicity.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Vincristine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Vincristine.Approved
AcetaminophenThe serum concentration of Vincristine can be increased when it is combined with Acetaminophen.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Vincristine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vincristine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Vincristine.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Vincristine.Approved, Vet Approved
AfatinibThe serum concentration of Vincristine can be increased when it is combined with Afatinib.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Vincristine.Approved
AlbendazoleThe serum concentration of Vincristine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Vincristine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Vincristine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Vincristine can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Vincristine.Approved, Investigational
AmantadineThe serum concentration of Vincristine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Vincristine.Approved, Investigational
Aminohippuric acidThe serum concentration of Vincristine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Vincristine can be increased when it is combined with Amiodarone.Approved, Investigational
AmiodaroneThe metabolism of Vincristine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Vincristine can be increased when it is combined with Amitriptyline.Approved
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Vincristine.Approved
AmlodipineThe serum concentration of Vincristine can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Vincristine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Vincristine can be increased when it is combined with Amsacrine.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Vincristine.Approved
AprepitantThe serum concentration of Vincristine can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vincristine.Approved, Investigational
AstemizoleThe serum concentration of Vincristine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Vincristine can be increased when it is combined with Atazanavir.Approved, Investigational
AtazanavirThe metabolism of Vincristine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Vincristine can be increased when it is combined with Atenolol.Approved
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Vincristine.Approved
AtomoxetineThe metabolism of Vincristine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Vincristine can be increased when it is combined with Atorvastatin.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Vincristine is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Vincristine.Approved, Investigational
AzelastineThe serum concentration of Vincristine can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Vincristine can be increased when it is combined with Azithromycin.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Vincristine.Investigational
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Vincristine.Approved, Investigational
BenzocaineThe serum concentration of Vincristine can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Vincristine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Vincristine.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Vincristine.Approved, Investigational
BiperidenThe serum concentration of Vincristine can be increased when it is combined with Biperiden.Approved
BoceprevirThe serum concentration of Vincristine can be increased when it is combined with Boceprevir.Withdrawn
BoceprevirThe metabolism of Vincristine can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Vincristine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Vincristine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Vincristine can be increased when it is combined with Bosutinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Vincristine.Approved
BromocriptineThe serum concentration of Vincristine can be increased when it is combined with Bromocriptine.Approved, Investigational
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Vincristine.Approved, Investigational
BuprenorphineThe serum concentration of Vincristine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Vincristine can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Vincristine can be increased when it is combined with Cabazitaxel.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vincristine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Vincristine.Approved
CaffeineThe serum concentration of Vincristine can be increased when it is combined with Caffeine.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Vincristine.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Vincristine.Experimental
CanagliflozinThe serum concentration of Vincristine can be increased when it is combined with Canagliflozin.Approved
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Vincristine.Approved
Candesartan cilexetilThe serum concentration of Vincristine can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Vincristine can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Vincristine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbamazepineThe metabolism of Vincristine can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Vincristine can be increased when it is combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Vincristine.Approved
CarvedilolThe serum concentration of Vincristine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Vincristine can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Vincristine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Vincristine.Withdrawn
ChloroquineThe serum concentration of Vincristine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Vincristine can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Vincristine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Vincristine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Vincristine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Vincristine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Vincristine can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Vincristine can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Vincristine can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Vincristine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Vincristine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Vincristine.Approved
CitalopramThe serum concentration of Vincristine can be increased when it is combined with Citalopram.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Vincristine.Approved
ClarithromycinThe serum concentration of Vincristine can be increased when it is combined with Clarithromycin.Approved
ClarithromycinThe metabolism of Vincristine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Vincristine can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Vincristine.Approved, Illicit
ClofazimineThe serum concentration of Vincristine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Vincristine.Approved, Investigational
ClomipramineThe serum concentration of Vincristine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Vincristine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Vincristine.Approved, Nutraceutical
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vincristine.Approved
ClotrimazoleThe serum concentration of Vincristine can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClotrimazoleThe metabolism of Vincristine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Vincristine.Approved
CobicistatThe serum concentration of Vincristine can be increased when it is combined with Cobicistat.Approved
CobicistatThe metabolism of Vincristine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Vincristine.Approved
ColchicineThe serum concentration of Vincristine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Vincristine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Vincristine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Vincristine.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Vincristine.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vincristine.Approved
CrizotinibThe serum concentration of Vincristine can be increased when it is combined with Crizotinib.Approved
CrizotinibThe metabolism of Vincristine can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Vincristine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Vincristine.Approved, Investigational
CyclosporineThe serum concentration of Vincristine can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Vincristine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Vincristine.Experimental
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vincristine.Approved
DabrafenibThe serum concentration of Vincristine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Vincristine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Vincristine can be increased when it is combined with Dactinomycin.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Vincristine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Vincristine.Approved
DarunavirThe serum concentration of Vincristine can be increased when it is combined with Darunavir.Approved
DarunavirThe metabolism of Vincristine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Vincristine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Vincristine can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Vincristine.Approved
DeferasiroxThe serum concentration of Vincristine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Vincristine can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Vincristine.Approved
DesipramineThe serum concentration of Vincristine can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vincristine.Approved
DesloratadineThe serum concentration of Vincristine can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Vincristine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Vincristine can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Vincristine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Vincristine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vincristine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Vincristine.Approved
DigoxinThe serum concentration of Vincristine can be decreased when it is combined with Digoxin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Vincristine.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Vincristine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Vincristine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Vincristine.Experimental
DihydroergotamineThe serum concentration of Vincristine can be increased when it is combined with Dihydroergotamine.Approved
DihydroergotamineThe metabolism of Vincristine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Vincristine.Illicit
DiltiazemThe serum concentration of Vincristine can be increased when it is combined with Diltiazem.Approved
DiltiazemThe metabolism of Vincristine can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Vincristine can be increased when it is combined with Dipyridamole.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Vincristine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vincristine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Vincristine.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Vincristine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Vincristine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Vincristine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Vincristine.Approved, Investigational
DoxycyclineThe metabolism of Vincristine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Vincristine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Vincristine can be increased when it is combined with Dronedarone.Approved
DronedaroneThe metabolism of Vincristine can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Vincristine.Approved
ElbasvirThe serum concentration of Vincristine can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Vincristine.Approved, Investigational
EltrombopagThe serum concentration of Vincristine can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Vincristine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Vincristine can be increased when it is combined with Enasidenib.Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Vincristine.Approved
EnzalutamideThe serum concentration of Vincristine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Vincristine.Approved, Investigational
ErgonovineThe serum concentration of Vincristine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Vincristine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Vincristine.Approved, Investigational
ErythromycinThe serum concentration of Vincristine can be decreased when it is combined with Erythromycin.Approved, Vet Approved
ErythromycinThe serum concentration of Vincristine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Vincristine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Vincristine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Vincristine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Vincristine can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Vincristine.Approved
EtoposideThe serum concentration of Vincristine can be increased when it is combined with Etoposide.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Vincristine.Approved
EtravirineThe serum concentration of Vincristine can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Vincristine.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Vincristine.Approved
FelodipineThe serum concentration of Vincristine can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Vincristine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Vincristine.Approved
FexofenadineThe serum concentration of Vincristine can be increased when it is combined with Fexofenadine.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Vincristine.Approved
FidaxomicinThe serum concentration of Vincristine can be increased when it is combined with Fidaxomicin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Vincristine.Approved
FingolimodVincristine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Vincristine can be increased when it is combined with Fluconazole.Approved
FluconazoleThe metabolism of Vincristine can be decreased when combined with Fluconazole.Approved
FluoxetineThe serum concentration of Vincristine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Vincristine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Vincristine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Vincristine can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Vincristine.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Vincristine.Approved
FluvoxamineThe serum concentration of Vincristine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FluvoxamineThe metabolism of Vincristine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Vincristine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Vincristine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Vincristine can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Vincristine can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Vincristine.Investigational
GefitinibThe serum concentration of Vincristine can be increased when it is combined with Gefitinib.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Vincristine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Vincristine.Approved
GenisteinThe serum concentration of Vincristine can be increased when it is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Vincristine.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Vincristine.Experimental
GlecaprevirThe serum concentration of Vincristine can be increased when it is combined with Glecaprevir.Approved
GlecaprevirThe serum concentration of Glecaprevir can be decreased when it is combined with Vincristine.Approved
GlyburideThe serum concentration of Vincristine can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Vincristine can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Vincristine can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Vincristine.Approved
GrepafloxacinThe serum concentration of Vincristine can be increased when it is combined with Grepafloxacin.Withdrawn
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Vincristine.Withdrawn
HaloperidolThe serum concentration of Vincristine can be increased when it is combined with Haloperidol.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Vincristine.Approved
HydrocortisoneThe serum concentration of Vincristine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Vincristine.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Vincristine.Approved
IdelalisibThe serum concentration of Vincristine can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Vincristine can be increased when it is combined with Imatinib.Approved
ImatinibThe metabolism of Vincristine can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Vincristine can be increased when it is combined with Imipramine.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Vincristine.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Vincristine.Approved
IndinavirThe serum concentration of Vincristine can be increased when it is combined with Indinavir.Approved
IndinavirThe metabolism of Vincristine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Vincristine can be increased when it is combined with Indomethacin.Approved, Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Vincristine.Approved, Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Vincristine.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Vincristine.Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Vincristine.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Vincristine.Approved, Investigational
IsavuconazoniumThe serum concentration of Vincristine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsavuconazoniumThe metabolism of Vincristine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Vincristine can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Vincristine can be increased when it is combined with Itraconazole.Approved, Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Vincristine.Approved, Investigational
IvacaftorThe serum concentration of Vincristine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Vincristine can be increased when it is combined with Ivermectin.Approved, Vet Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Vincristine.Approved, Vet Approved
JosamycinThe serum concentration of Vincristine can be increased when it is combined with Josamycin.Approved
KetamineThe serum concentration of Vincristine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Vincristine.Approved
KetoconazoleThe serum concentration of Vincristine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Vincristine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Vincristine can be increased when it is combined with Kitasamycin.Experimental
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Vincristine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Vincristine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Vincristine.Experimental
LansoprazoleThe serum concentration of Vincristine can be increased when it is combined with Lansoprazole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Vincristine.Approved, Investigational
LapatinibThe serum concentration of Vincristine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Vincristine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Vincristine is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Vincristine.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Vincristine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Vincristine.Approved, Investigational
LevofloxacinThe serum concentration of Vincristine can be increased when it is combined with Levofloxacin.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Vincristine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Vincristine.Approved
LevothyroxineThe serum concentration of Vincristine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Vincristine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Vincristine.Approved
LiothyronineThe serum concentration of Vincristine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Vincristine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Vincristine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Vincristine.Approved
LomitapideThe serum concentration of Vincristine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Vincristine can be increased when it is combined with Loperamide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Vincristine.Approved
LopinavirThe serum concentration of Vincristine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Vincristine can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Vincristine can be increased when it is combined with Losartan.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Vincristine.Approved
LovastatinThe serum concentration of Vincristine can be increased when it is combined with Lovastatin.Approved, Investigational
LovastatinThe metabolism of Vincristine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Vincristine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Vincristine can be decreased when it is combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Vincristine.Illicit, Withdrawn
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Vincristine.Approved, Investigational
MaprotilineThe serum concentration of Vincristine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Vincristine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Vincristine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Vincristine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Vincristine can be increased when it is combined with Meprobamate.Approved, Illicit
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Vincristine.Experimental
MethadoneThe serum concentration of Vincristine can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Vincristine.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Vincristine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Vincristine.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Vincristine.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Vincristine.Experimental
MetoprololThe serum concentration of Vincristine can be increased when it is combined with Metoprolol.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Vincristine.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Vincristine.Experimental
MibefradilThe serum concentration of Vincristine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Vincristine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Vincristine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Vincristine can be decreased when it is combined with Mifepristone.Approved, Investigational
MifepristoneThe serum concentration of Vincristine can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Vincristine.Approved
MitomycinThe serum concentration of Vincristine can be increased when it is combined with Mitomycin.Approved
MitomycinThe risk or severity of adverse effects can be increased when Vincristine is combined with Mitomycin.Approved
MitotaneThe serum concentration of Vincristine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Vincristine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Vincristine can be increased when it is combined with Morphine.Approved, Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Vincristine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vincristine.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Vincristine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Vincristine.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Vincristine.Approved, Vet Approved
NaltrexoneThe serum concentration of Vincristine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Vincristine can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Vincristine is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Vincristine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NefazodoneThe metabolism of Vincristine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Vincristine can be increased when it is combined with Nelfinavir.Approved
NelfinavirThe metabolism of Vincristine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Vincristine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Vincristine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Vincristine can be decreased when it is combined with Nevirapine.Approved
NevirapineThe metabolism of Vincristine can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Vincristine can be increased when it is combined with Nicardipine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Vincristine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Vincristine.Approved
NifedipineThe serum concentration of Vincristine can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Vincristine can be increased when it is combined with Nilotinib.Approved, Investigational
NilotinibThe metabolism of Vincristine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Vincristine.Approved
NisoldipineThe serum concentration of Vincristine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Vincristine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Vincristine can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Vincristine.Approved
NorethisteroneThe serum concentration of Vincristine can be decreased when it is combined with Norethisterone.Approved
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Vincristine.Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Vincristine.Approved, Investigational
OlaparibThe metabolism of Vincristine can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Vincristine can be increased when it is combined with Oleandomycin.Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Vincristine.Experimental
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Vincristine.Approved
OmeprazoleThe serum concentration of Vincristine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Vincristine can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Vincristine.Approved
P-NitrophenolThe serum concentration of Vincristine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Vincristine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vincristine.Approved, Vet Approved
PalbociclibThe serum concentration of Vincristine can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Vincristine can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Vincristine.Approved, Investigational
PantoprazoleThe serum concentration of Vincristine can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Vincristine can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Vincristine.Approved
PentobarbitalThe serum concentration of Vincristine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentobarbitalThe metabolism of Vincristine can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Vincristine.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Vincristine can be increased when it is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Vincristine.Experimental
PhenobarbitalThe serum concentration of Vincristine can be decreased when it is combined with Phenobarbital.Approved
PhenobarbitalThe metabolism of Vincristine can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Vincristine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Vincristine can be increased when it is combined with Pibrentasvir.Approved
PibrentasvirThe serum concentration of Pibrentasvir can be decreased when it is combined with Vincristine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vincristine.Approved, Investigational
PimozideThe serum concentration of Vincristine can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Vincristine.Approved
Platelet Activating FactorThe serum concentration of Vincristine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Vincristine.Approved
PonatinibThe serum concentration of Vincristine can be increased when it is combined with Ponatinib.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Vincristine.Approved
PosaconazoleThe serum concentration of Vincristine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vincristine.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Vincristine can be increased when it is combined with Pravastatin.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Vincristine.Approved
PrazosinThe serum concentration of Vincristine can be increased when it is combined with Prazosin.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Vincristine.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Vincristine.Approved, Vet Approved
PrednisoneThe serum concentration of Vincristine can be increased when it is combined with Prednisone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Vincristine.Approved, Vet Approved
PrimidoneThe serum concentration of Vincristine can be decreased when it is combined with Primidone.Approved, Vet Approved
PrimidoneThe metabolism of Vincristine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Vincristine can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Vincristine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Vincristine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Vincristine can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Vincristine can be increased when it is combined with Propranolol.Approved, Investigational
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Vincristine.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Vincristine.Experimental
ProtriptylineThe serum concentration of Vincristine can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Vincristine.Approved
QuercetinThe serum concentration of Vincristine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Vincristine.Approved
QuinacrineThe serum concentration of Vincristine can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Vincristine can be increased when it is combined with Quinidine.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Vincristine.Approved
QuinineThe serum concentration of Vincristine can be increased when it is combined with Quinine.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Vincristine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Vincristine is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vincristine.Approved
RanitidineThe serum concentration of Vincristine can be increased when it is combined with Ranitidine.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Vincristine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Vincristine.Approved, Investigational
ReboxetineThe serum concentration of Vincristine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Vincristine can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Vincristine can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Vincristine can be decreased when it is combined with Rifabutin.Approved
RifabutinThe metabolism of Vincristine can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Vincristine can be decreased when it is combined with Rifampicin.Approved
RifampicinThe metabolism of Vincristine can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Vincristine can be decreased when it is combined with Rifapentine.Approved
RifapentineThe metabolism of Vincristine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Vincristine.Approved, Investigational
RilpivirineThe serum concentration of Vincristine can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Vincristine.Investigational
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Vincristine.Approved, Investigational
RitonavirThe serum concentration of Vincristine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Vincristine.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Vincristine.Approved
RolapitantThe serum concentration of Vincristine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Vincristine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Vincristine.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Vincristine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Vincristine.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Vincristine.Approved, Vet Approved
SaquinavirThe serum concentration of Vincristine can be increased when it is combined with Saquinavir.Approved, Investigational
SaquinavirThe metabolism of Vincristine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Vincristine can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Vincristine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Vincristine.Approved
SertralineThe serum concentration of Vincristine can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Vincristine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Vincristine.Approved
SiltuximabThe serum concentration of Vincristine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Vincristine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Vincristine can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vincristine.Approved
SirolimusThe serum concentration of Vincristine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Vincristine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Vincristine.Approved
SolithromycinThe serum concentration of Vincristine can be increased when it is combined with Solithromycin.Investigational
SorafenibThe serum concentration of Vincristine can be increased when it is combined with Sorafenib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Vincristine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Vincristine.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Vincristine.Experimental
SpiramycinThe serum concentration of Vincristine can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe serum concentration of Vincristine can be increased when it is combined with Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Vincristine.Investigational
St. John's WortThe serum concentration of Vincristine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Vincristine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Vincristine can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Vincristine can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Vincristine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Vincristine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Vincristine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Vincristine can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Vincristine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Vincristine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Vincristine.Approved, Investigational
TamoxifenThe serum concentration of Vincristine can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Vincristine can be increased when it is combined with Taurocholic Acid.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Vincristine.Experimental
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Vincristine.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Vincristine.Approved
TelaprevirThe serum concentration of Vincristine can be increased when it is combined with Telaprevir.Withdrawn
TelaprevirThe metabolism of Vincristine can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Vincristine can be increased when it is combined with Telithromycin.Approved
TelithromycinThe metabolism of Vincristine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Vincristine can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Vincristine can be increased when it is combined with Temsirolimus.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Vincristine.Approved
TeniposideTeniposide may increase the neurotoxic activities of Vincristine.Approved
TerazosinThe serum concentration of Vincristine can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Vincristine can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Vincristine.Experimental
TeriflunomideThe serum concentration of Vincristine can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Vincristine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Vincristine can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Vincristine.Investigational
TicagrelorThe serum concentration of Vincristine can be increased when it is combined with Ticagrelor.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Vincristine.Approved
TiclopidineThe metabolism of Vincristine can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Vincristine.Approved
TocilizumabThe serum concentration of Vincristine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibVincristine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Vincristine can be increased when it is combined with Tolvaptan.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Vincristine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Vincristine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Vincristine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Vincristine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Vincristine.Approved
TrazodoneThe serum concentration of Vincristine can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Vincristine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Vincristine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Vincristine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Vincristine can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Vincristine can be increased when it is combined with Troleandomycin.Approved
TylosinThe serum concentration of Vincristine can be increased when it is combined with Tylosin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Vincristine.Experimental
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Vincristine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Vincristine.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Vincristine.Approved
VelpatasvirThe serum concentration of Vincristine can be increased when it is combined with Velpatasvir.Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Vincristine.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Vincristine.Approved
VenlafaxineThe serum concentration of Vincristine can be increased when it is combined with Venlafaxine.Approved
VenlafaxineThe metabolism of Vincristine can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Vincristine can be decreased when it is combined with Verapamil.Approved
VerapamilThe metabolism of Vincristine can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vincristine can be decreased when it is combined with Vinblastine.Approved
VinorelbineThe serum concentration of Vincristine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Vincristine.Approved
VoriconazoleThe serum concentration of Vincristine can be increased when it is combined with Voriconazole.Approved, Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Vincristine.Approved, Investigational
VoxilaprevirThe serum concentration of Vincristine can be increased when it is combined with Voxilaprevir.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Vincristine.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Vincristine.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Vincristine.Approved
ZimelidineThe serum concentration of Vincristine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Vincristine can be decreased when combined with Ziprasidone.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Vincristine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Homer L. Pearce, "Method of preparing vincristine." U.S. Patent US4303584, issued November, 1967.

US4303584
General References
  1. Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996 Apr 1;77(7):1356-62. [PubMed:8608515]
  2. Qweider M, Gilsbach JM, Rohde V: Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007 Mar;6(3):280-3. [PubMed:17355029]
  3. JOHNSON IS, ARMSTRONG JG, GORMAN M, BURNETT JP Jr: THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res. 1963 Sep;23:1390-427. [PubMed:14070392]
  4. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS: Vincristine revisited. Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87. [PubMed:10226730]
External Links
Human Metabolome Database
HMDB14681
KEGG Drug
D08679
KEGG Compound
C07204
PubChem Compound
5978
PubChem Substance
46507033
ChemSpider
5758
BindingDB
50139772
ChEBI
28445
ChEMBL
CHEMBL90555
Therapeutic Targets Database
DAP000114
PharmGKB
PA451879
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Vincristine
ATC Codes
L01CA02 — Vincristine
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (362 KB)
MSDS
Download (90.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedBasic ScienceChronic Lymphocytic Leukaemia (CLL)1
0WithdrawnTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Neurotoxicity1
1Active Not RecruitingOtherPediatric Oncology1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
1Active Not RecruitingTreatmentBurkitt's Lymphoma / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1Active Not RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1CompletedTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia, Lymphocytic / Leukemias1
1CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1CompletedTreatmentBone Marrow Suppression / Brain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ1
1CompletedTreatmentBrain and Central Nervous System Tumors / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentEwing's Sarcoma (ES) / Neuroectodermal Tumors, Primitive / Neuroepithelioma / Sarcoma, Osteogenic / Sarcomas1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)3
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemias / Malignant Lymphomas2
1CompletedTreatmentLymphoblastic Leukemia, Acute, Childhood1
1CompletedTreatmentLymphoma, Large-Cell, Anaplastic / Lymphoma, NK-cell / T-Cell Lymphomas1
1CompletedTreatmentMalignant Lymphomas3
1CompletedTreatmentMalignant Melanoma1
1CompletedTreatmentNeoplasms, Brain / Neuroblastomas / Sarcomas / Tumors, Central Nervous System1
1CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System2
1CompletedTreatmentNeuroblastomas3
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
1CompletedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1CompletedTreatmentRecurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRefractory Solid Tumors in Children1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentCD20 Positive / HIV Positivity / Lymphoma, AIDS Related / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1Not Yet RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / B-cell Adult Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Adult Acute Lymphoblastic Leukemia / Lymphoma, Lymphoblastic / T-cell Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAcute Lymphocytic Leukemia (ALL)1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentDiffuse Large B-Cell Lymphoma, Lymphoma Follicular / Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular1
1RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell, Marginal Zone / Lymphoma, Mantle-Cell / Lymphoma, Small-Cell / Non-Hodgkin's Lymphoma (NHL) / Waldenstrom's Macroglobulinemia (WM)1
1RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentHigh Grade B-cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentNeoplasms Metastasis1
1RecruitingTreatmentNeuroblastomas / Recurrent Neuroblastoma1
1RecruitingTreatmentPrimary Brain Tumors / Tumors, Solid1
1RecruitingTreatmentRecurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1TerminatedTreatmentAcute Leukemias of Ambiguous Lineage / Acute Undifferentiated Leukemia (AUL) / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Small Intestine Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1TerminatedTreatmentAcute Lymphoblastic Leukaemia Recurrent / Allergy to Native e.Coli Asparaginase / Allergy to PEG e.Coli Asparaginase1
1TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia, Lymphocytic, Acute / Leukemias1
1TerminatedTreatmentBone Cancer / Kidney Tumors / Neoplasms / Neuroblastomas / Tumors, Solid1
1TerminatedTreatmentFollicular Lymphoma (FL)1
1TerminatedTreatmentLeukemia, Lymphoblastic, Acute / Leukemia, Lymphoblastic, Acute, T Cell / Lymphoblastic Leukemia, Acute / Lymphoblastic Leukemia, Acute, Childhood1
1TerminatedTreatmentMixed Phenotype Acute Leukemia (MPAL) / Relapsed or Refractory Acute Lymphoblastic Leukemia / Relapsed or Refractory Lymphoblastic Lymphoma1
1Unknown StatusTreatmentMalignant Lymphomas1
1Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
1WithdrawnTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1WithdrawnTreatmentRecurrent Adult Acute Lymphoblastic Leukemia / Refractory Adult Acute Lymphoblastic Leukemia1
1, 2Active Not RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / CD20 Positive / Grade 3b Follicular Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Plasmablastic Lymphoma / Primary Effusion Lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1, 2Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma Refractory / Diffuse Large B Cell Lymphoma Relapsed1
1, 2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentMedulloblastomas1
1, 2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)2
1, 2Active Not RecruitingTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2Active Not RecruitingTreatmentStage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)2
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAcute Undifferentiated Leukemia (AUL) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / L1 Adult Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Adult Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma Unspecified1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Neoplasms, Brain / Neuroblastomas / Sarcomas / Wilms' tumor1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentMalignant Lymphomas3
1, 2CompletedTreatmentMalignant Lymphomas / Non Hodgkin Lymphoma (NHL)1
1, 2Not Yet RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2Not Yet RecruitingTreatmentDiffuse B-Cell Lymphoma1
1, 2RecruitingTreatmentALK- Anaplastic Large Cell Lymphoma (ALCL) / ALK- Anaplastic Largecell Lymphoma (ALCL) / Angioimmunoblastic T-cell Lymphoma (AITL) / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS) / PTCL-NOS1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1, 2RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentAnaplastic Astrocytoma (AA) / Brain Stem Gliomas / Diffuse Intrinsic Pontine Glioma (DIPG) / DIPG / Glioblastoma Multiforme / Glioma, Astrocytic / Gliosarcoma / Low-Grade Gliomas / Optic Nerve Glioma / Pilocytic Astrocytoma / Pilomyxoid Astrocytoma / Pleomorphic Xanthoastrocytoma1
1, 2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma1
1, 2RecruitingTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2RecruitingTreatmentLymphoma, B-Cell / Primary Effusion Lymphomas1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Precursor B-Cell Lymphoblastic Leukemia / Precursor T-Cell Lymphoblastic Leukemia1
1, 2TerminatedTreatmentMalignant Lymphomas1
1, 2Unknown StatusTreatmentMalignant Lymphomas2
1, 2WithdrawnTreatmentLarge Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease / Primary Effusion Lymphomas1
1, 2WithdrawnTreatmentLarge-Cell Lymphoma, Diffuse / Lymphoma, Diffuse Large-Cell / Lymphoma, Diffuse Large-Cell B-cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingSupportive CareLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Ph Positive Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentCD20 Positive / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentChemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Malignant Lymphomas / Neurotoxicity / Radiation Toxicity1
2Active Not RecruitingTreatmentDe Novo / Low-dose Corticosteroids Pretreatment / Secondary / Untreated Philadelphia Positive Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentHigh Risk Supratentorial PNET / Metastatic Medulloblastoma / Metastatic PNET1
2Active Not RecruitingTreatmentLeukaemia, Lymphoblastic / Lymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLymphoma, B-Cell1
2Active Not RecruitingTreatmentLymphoma, Hodgkins1
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Active Not RecruitingTreatmentMalignant Lymphomas11
2Active Not RecruitingTreatmentMalignant Lymphomas / Nonneoplastic Condition1
2Active Not RecruitingTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentNeurofibromatosis 11
2Active Not RecruitingTreatmentPrimary Mediastinal Large B Cell Lymphoma1
2Active Not RecruitingTreatmentRetinoblastoma1
2Active Not RecruitingTreatmentSarcomas1
2CompletedDiagnosticMalignant Lymphomas1
2CompletedPreventionOral Mucositis / Sarcomas1
2CompletedSupportive CareBrain and Central Nervous System Tumors1
2CompletedTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)5
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2CompletedTreatmentAcute Lymphoblastic Leukemia, Mature B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL)1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAlveolar Childhood Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBlast Crisis / Leukemia, Lymphocytic, Acute / Leukemia,Myeloid, Chronic / Philadelphia Chromosome1
2CompletedTreatmentBrain and Central Nervous System Tumors6
2CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
2CompletedTreatmentBurkitt's Lymphoma / Burkitt'S-like Lymphoma1
2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor1
2CompletedTreatmentCancer, Ovarian / Sarcomas / Small Intestine Cancer1
2CompletedTreatmentCarcinoma, Adrenal Cortical1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentChildhood Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Clear Cell Sarcoma of the Kidney / Papillary Renal Cell Carcinoma / Rhabdoid Tumors of the Kidney (RTK) / Stage I Renal Cell Cancer / Stage I Renal Wilms Tumor / Stage II Renal Cell Cancer / Stage II Renal Wilms Tumor / Stage III Renal Cell Cancer / Stage III Renal Wilms Tumor / Stage IV Renal Cell Cancer / Stage IV Renal Wilms Tumor1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
2CompletedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentEwing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Peripheral Primitive Neuroectodermal Tumor / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2CompletedTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas1
2CompletedTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
2CompletedTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma1
2CompletedTreatmentFollicular Lymphoma (FL)1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD) / Pediatric1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, AIDS Related1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLeukemia, Lymphocytic, Acute1
2CompletedTreatmentLeukemias13
2CompletedTreatmentLeukemias / Malignant Lymphomas7
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myleoma / Myelodysplastic Syndrome / Myeloproliferative Disorders1
2CompletedTreatmentLeukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentLymphoma, B-Cell1
2CompletedTreatmentLymphoma, Hodgkins1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / POOR PROGNOSIS1
2CompletedTreatmentMalignant Lymphomas41
2CompletedTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentMalignant Lymphomas / Neurotoxicity1
2CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer1
2CompletedTreatmentMantle Cell Lymphoma (MCL)3
2CompletedTreatmentMetastatic Malignant Uveal Melanoma1
2CompletedTreatmentMultiple Myeloma (MM)2
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
2CompletedTreatmentNeoplasms, Brain / Neuroblastomas / Tumors, Central Nervous System1
2CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
2CompletedTreatmentNeuroblastomas9
2CompletedTreatmentNeutropenias / Sarcomas1
2CompletedTreatmentNon-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
2CompletedTreatmentRenal Cancers / Sarcomas1
2CompletedTreatmentRetinoblastoma2
2CompletedTreatmentSarcomas5
2CompletedTreatmentUntreated Childhood Medulloblastoma1
2CompletedTreatmentUntreated T-Cell Angioimmunoblastic Lymphoma1
2Enrolling by InvitationTreatmentAcute,Leukemia, Lymphoid1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Burkitt Leukemia/Lymphoma / Hematopoietic/Lymphoid Cancer / Lymphoma, Lymphoblastic1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)1
2Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent B Lymphoblastic Lymphoma / Recurrent T Lymphoblastic Leukemia/Lymphoma / Refractory B Lymphoblastic Lymphoma / Refractory T Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
2Not Yet RecruitingTreatmentUntreated Childhood Medulloblastoma1
2RecruitingSupportive CareSarcomas1
2RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / Philadelphia Chromosome Positive / Recurrent Adult Acute Lymphoblastic Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / CD20 Positive / Philadelphia Chromosome Positive1
2RecruitingTreatmentAll1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2RecruitingTreatmentAtypical Teratoid Rhabdoid Tumors (ATRT) / Malignant Rhabdoid Tumors (MRT)1
2RecruitingTreatmentB-cell Acute Lymphoblastic Leukemia1
2RecruitingTreatmentChildren / Retinal Neoplasms / Retinoblastoma1
2RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentEwing's Sarcoma (ES)1
2RecruitingTreatmentFollicular Lymphoma, Grade 3b / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Transformed Lymphoma / DLBCL1
2RecruitingTreatmentGrade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma1
2RecruitingTreatmentHHV-8 / Human Immunodeficiency Virus (HIV) / Lymphoproliferative Disorders / Malignancies1
2RecruitingTreatmentHaemangioma-thrombocytopenia syndrome / Kaposiform Hemangioendothelioma (KHE) / Tufted Angioma1
2RecruitingTreatmentHodgkins Disease (HD)1
2RecruitingTreatmentLeukaemia, Lymphoblastic1
2RecruitingTreatmentLeukemia, Lymphoblastic, Acute / Leukemias / Lymphoma, Lymphoblastic1
2RecruitingTreatmentLeukemias7
2RecruitingTreatmentLymphoma, Hodgkins2
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
2RecruitingTreatmentLymphoma, Mantle-Cell / Malignant Lymphomas1
2RecruitingTreatmentMalignant Lymphomas2
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentNeuroblastomas1
2RecruitingTreatmentNewly Diagnosed Ewing Sarcoma1
2RecruitingTreatmentPosttransplant Lymphoproliferative Disorder1
2RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentRetinoblastoma2
2RecruitingTreatmentRhabdomyosarcomas2
2RecruitingTreatmentStage I Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2SuspendedTreatmentMalignant Lymphomas1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2TerminatedTreatmentAnaplastic Large Cell Lymphoma1
2TerminatedTreatmentAtypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentBone Cancer / Ewing's Sarcoma (ES)1
2TerminatedTreatmentCancers / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2TerminatedTreatmentEwing's Sarcoma (ES)1
2TerminatedTreatmentHemangiomas1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Lymphoma, Lymphoblastic / Malignant Lymphomas / Precursor-B Acute Lymphoblastic Leukemia1
2TerminatedTreatmentLeukemias / Malignant Lymphomas1
2TerminatedTreatmentLung Cancers1
2TerminatedTreatmentLymphatic Diseases / Lymphoma, B-Cell1
2TerminatedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentMalignant Lymphomas3
2TerminatedTreatmentMedulloblastomas / Neoplasms, Brain / Primitive Neuroectodermal Tumor / Tumors, Central Nervous System1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentRecurrent Adult Acute Lymphoblastic Leukemia1
2TerminatedTreatmentSarcomas1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2TerminatedTreatmentTreatment Refusal1
2Unknown StatusTreatmentAnaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL)1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors2
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
2Unknown StatusTreatmentHIV-associated Hodgkin Lymphoma1
2Unknown StatusTreatmentLeukemias2
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2Unknown StatusTreatmentLymphoid Blastic Phase of Chronic Myeloid Leukemia / Philadelphia Positive Acute Lymphoblastic Leukemia1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentLymphoma, Mantle-Cell1
2Unknown StatusTreatmentMalignant Lymphomas9
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentNHL With Hemophagocytic Lymphohistiocytosis1
2Unknown StatusTreatmentNeuroblastomas2
2Unknown StatusTreatmentRenal Cancers1
2Unknown StatusTreatmentSarcomas2
2Unknown StatusTreatmentTumors, Central Nervous System1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Retinoblastoma / Sarcomas1
2WithdrawnTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2WithdrawnTreatmentMalignant Lymphomas2
2, 3Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3CompletedTreatmentImmune Thrombocytopenic Purpura ( ITP )1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3RecruitingTreatmentChildhood Ependymoma1
2, 3RecruitingTreatmentLeukemias1
2, 3RecruitingTreatmentMature B-Cell Lymphoma1
2, 3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
2, 3RecruitingTreatmentNeoplasms, Brain1
2, 3TerminatedTreatmentMalignant Lymphomas1
2, 3Unknown StatusTreatmentLeukemias1
3Active Not RecruitingNot AvailableBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Children / Ototoxicity1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAdult Malignant Mesenchymoma / Adult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Botryoid-Type Embryonal Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Childhood Malignant Mesenchymoma / Non-Metastatic Childhood Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
3Active Not RecruitingTreatmentAdult Renal Wilms Tumor / Beckwith-Wiedemann Syndrome / Childhood Renal Wilms Tumor / Diffuse Hyperplastic Perilobar Nephroblastomatosis / Hemihypertrophy / Stage I Renal Wilms Tumor / Stage II Renal Wilms Tumor / Stage III Renal Wilms Tumor / Stage IV Renal Wilms Tumor / Stage V Renal Wilms Tumor1
3Active Not RecruitingTreatmentAdult Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Previously Untreated Childhood Rhabdomyosarcoma1
3Active Not RecruitingTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Childhood Supratentorial Primitive Neuroectodermal Tumor / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Peripheral Primitive Neuroectodermal Tumor of the Kidney / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Non Hodgkin's Lymphoma / Mature B-cell Leukemia Burkitt-type1
3Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChildhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChoroid Plexus Tumors1
3Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma CD20 Positive / Diffuse Large B Cell Lymphoma CD20+1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentExtraocular Retinoblastoma1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL)1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoplasmacytic Lymphoma / Marginal Zone Lymphoma / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentIntraocular Retinoblastoma1
3Active Not RecruitingTreatmentLarge B Cell Lymphoma1
3Active Not RecruitingTreatmentLeukemias2
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute1
3Active Not RecruitingTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentLymphoma, Hodgkins2
3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentLymphoma, Mantle-Cell1
3Active Not RecruitingTreatmentMalignant Lymphomas10
3Active Not RecruitingTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentRetinal Neoplasms / Retinoblastoma1
3Active Not RecruitingTreatmentSarcomas1
3Active Not RecruitingTreatmentStage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q / Stage IV Wilms Tumor1
3CompletedPreventionCancers1
3CompletedSupportive CareCardiac Toxicity / Leukemias / Malignant Lymphomas1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)2
3CompletedTreatmentAdult Malignant Mesenchymoma / Adult Rhabdomyosarcoma / Alveolar Childhood Rhabdomyosarcoma / Childhood Malignant Mesenchymoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Nonmetastatic Childhood Soft Tissue Sarcoma / Previously Untreated Childhood Rhabdomyosarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma1
3CompletedTreatmentBrain and Central Nervous System Tumors4
3CompletedTreatmentCardiac Toxicity / Malignant Lymphomas2
3CompletedTreatmentCervical Cancers1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentChildhood Hepatoblastoma / Recurrent Childhood Liver Cancer / Stage I Childhood Liver Cancer1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentChildhood Malignant Fibrous Histiocytoma of Bone / Sarcomas1
3CompletedTreatmentColorectal Cancers1
3CompletedTreatmentElderly Patients (>65 Years) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentHead and Neck Carcinoma1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentIntraocular Retinoblastoma2
3CompletedTreatmentLeukemia, Myelocytic, Acute1
3CompletedTreatmentLeukemias14
3CompletedTreatmentLeukemias / Malignant Lymphomas4
3CompletedTreatmentLung Cancers2
3CompletedTreatmentLymphoma, Hodgkins3
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
3CompletedTreatmentM-Protein / Multiple Myeloma (MM) / Myeloma Proteins / Plasma Cell Myeloma1
3CompletedTreatmentMalignant Lymphomas16
3CompletedTreatmentMesothelioma, Malignant1
3CompletedTreatmentMultiple Myeloma (MM)2
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
3CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System2
3CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System / Untreated Childhood Medulloblastoma1
3CompletedTreatmentNeuroblastomas4
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
3CompletedTreatmentRenal Cancers2
3CompletedTreatmentSarcomas2
3CompletedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3CompletedTreatmentStage I Wilms Tumor / Stage II Wilms Tumor / Stage III Wilms Tumor1
3CompletedTreatmentStage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Small Lymphocytic Lymphoma1
3CompletedTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor2
3Not Yet RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / NMYC Gene Amplification / Recurrent Neuroblastoma1
3Not Yet RecruitingTreatmentGestational Trophoblastic Neoplasms1
3Not Yet RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3Not Yet RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Not Yet RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / BCR/ABL1 Fusion Protein Negative / Untreated Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAdult B Lymphoblastic Lymphoma / Childhood B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Lymphoblastic Lymphoma / Down Syndrome (DS) / Stage I B Lymphoblastic Lymphoma / Stage II B Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentBrain and Central Nervous System Tumors1
3RecruitingTreatmentChildhood Hodgkin Lymphoma / Classical Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
3RecruitingTreatmentChildhood Infratentorial Ependymoma / Childhood Supratentorial Ependymoma / Newly Diagnosed Childhood Ependymoma1
3RecruitingTreatmentClassical Hodgkin Lymphoma2
3RecruitingTreatmentEwing's Sarcoma (ES)1
3RecruitingTreatmentFollicular Lymphoma (FL)1
3RecruitingTreatmentFollicular Non-Hodgkin's Lymphoma1
3RecruitingTreatmentInfection, Human Immunodeficiency Virus I1
3RecruitingTreatmentLow Grade Glioma (LGG)1
3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)6
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingTreatmentMetastatic Ewing Sarcoma / Metastatic Malignant Neoplasm in the Bone / Metastatic Malignant Neoplasm in the Bone Marrow / Metastatic Malignant Neoplasm in the Lung / Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone / Peripheral Primitive Neuroectodermal Tumor of Soft Tissues1
3RecruitingTreatmentNeuroblastomas1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)2
3RecruitingTreatmentPRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3RecruitingTreatmentPhiladelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3SuspendedTreatmentBotryoid-Type Embryonal Rhabdomyosarcoma / Rhabdomyosarcoma, Alveolar / Rhabdomyosarcoma, Embryonal / Rhabdomyosarcomas / Sclerosing Rhabdomyosarcoma / Spindle Cell Rhabdomyosarcoma / Untreated Childhood Rhabdomyosarcoma1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3SuspendedTreatmentMalignant Lymphomas1
3TerminatedHealth Services ResearchFollicular Lymphoma (FL)1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)2
3TerminatedTreatmentLymphoma, B Cell1
3TerminatedTreatmentLymphoma, Extranodal NK-T-Cell1
3TerminatedTreatmentMalignant Lymphomas3
3TerminatedTreatmentMultiple Myeloma (MM)1
3Unknown StatusTreatmentAdult Acute Lymphoblastic Leukemia1
3Unknown StatusTreatmentBrain and Central Nervous System Tumors4
3Unknown StatusTreatmentCarcinoma of Unknown Primary1
3Unknown StatusTreatmentFollicular Lymphoma (FL)1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
3Unknown StatusTreatmentIPI≥2 / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Unknown StatusTreatmentLeukemias2
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentLeukemias / Mucositis / Oral Complications1
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
3Unknown StatusTreatmentLymphoma, Mantle-Cell1
3Unknown StatusTreatmentMalignant Lymphomas12
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
3Unknown StatusTreatmentNeuroblastomas5
3Unknown StatusTreatmentRenal Cancers2
3Unknown StatusTreatmentRetinoblastoma1
3Unknown StatusTreatmentSarcomas3
3WithdrawnTreatmentLeukemias1
3WithdrawnTreatmentSarcomas1
4Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)6
4CompletedTreatmentAdult Acute Lymphocytic Leukemia4
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentLymphoma, Lymphoblastic1
4Not Yet RecruitingTreatmentImmune Thrombocytopenia1
4RecruitingTreatmentALK-negative Anaplastic Large Cell Lymphoma / Angioimmunoblastic T Cell Lymphoma / Enteropathy Associated T Cell Lymphoma / Hepatosplenic T Cell Lymphoma / Peripherial T Cell Lymphoma,Not Otherwise Specified / Subcutaneous Panniculitis Like T Cell Lymphoma1
4RecruitingTreatmentAcute Lymphobkastic Leukemia1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)3
4RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Non-Hodgkin's Lymphoma (NHL)1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
4Unknown StatusTreatmentCancers1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableActive Not RecruitingTreatmentBrain and Central Nervous System Tumors1
Not AvailableActive Not RecruitingTreatmentChildhood Lymphocyte Predominant Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
Not AvailableActive Not RecruitingTreatmentLeukemias1
Not AvailableActive Not RecruitingTreatmentMedulloblastomas / Pinealoblastoma / Supratentorial Embryonal Tumor, Not Otherwise Specified / Untreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
Not AvailableActive Not RecruitingTreatmentPrimary Central Nervous System Neoplasms1
Not AvailableCompletedNot AvailableLymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedSupportive CareNausea / Sarcomas / Vomiting1
Not AvailableCompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T-Cell Leukemia/Lymphoma / Burkitt's Lymphoma / Lymphoid Malignancies (New or Relapsed) / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL)1
Not AvailableCompletedTreatmentAdverse Effects of Medical Drugs / Effects of Chemotherapy / Prophylaxis of acute chemotherapy induced nausea and vomiting / Sarcomas1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentCancer, Ovarian / Sarcomas1
Not AvailableCompletedTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableCompletedTreatmentEwing Sarcoma of Bone / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentL1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentLeukemia, Lymphocytic, Acute1
Not AvailableCompletedTreatmentLeukemias2
Not AvailableCompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Post Transplant Lymphoproliferative Disorder / Primary Mediastinal (Thymic) Large B-cell Lymphoma1
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentLymphoma, Lymphoblastic1
Not AvailableCompletedTreatmentMalignant Lymphomas3
Not AvailableCompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableNot Yet RecruitingTreatmentRecurrent High-grade Glioma1
Not AvailableRecruitingTreatmentAIDS Related Non-Hodgkin Lymphoma / AIDS-Related Burkitt Lymphoma / AIDS-Related Diffuse Large B-cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukemia Ph Positive1
Not AvailableRecruitingTreatmentAdvanced Intra-Ocular Retinoblastoma / Retinoblastoma1
Not AvailableRecruitingTreatmentClassical Hodgkins Lymphoma in Children and Adolescents1
Not AvailableRecruitingTreatmentComposite Lymphoma / Grade 3b Follicular Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Follicular Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Follicular Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Follicular Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Follicular Lymphoma1
Not AvailableRecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
Not AvailableRecruitingTreatmentMedulloblastomas1
Not AvailableRecruitingTreatmentNeuroblastomas2
Not AvailableRecruitingTreatmentPleuropulmonary Blastoma1
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableTerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentEwing's Sarcoma (ES)1
Not AvailableUnknown StatusTreatmentLeukemias2
Not AvailableUnknown StatusTreatmentMalignant Lymphomas2
Not AvailableUnknown StatusTreatmentNeuroblastomas1
Not AvailableUnknown StatusTreatmentRetinoblastoma1
Not AvailableWithdrawnNot AvailableLeukemias1
Not AvailableWithdrawnDiagnosticMalignant Lymphomas1
Not AvailableWithdrawnTreatmentMalignant Lymphomas1
Not AvailableWithdrawnTreatmentRetinoblastoma1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
  • Teva parenteral medicines inc
  • Bristol myers squibb
  • Abic ltd
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Kit
LiquidIntravenous1 mg
Injection, solutionIntravenous1 mg/mL
Powder, for solutionIntravenous5 mg
SolutionIntravenous1 mg
Prices
Unit descriptionCostUnit
Vincristine 2 mg/2 ml vial18.06USD ml
Oncovite tablet0.19USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6723338No2000-03-312020-03-31Us
US7887836No2000-03-312020-03-31Us
US7247316No2000-09-252020-09-25Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)220 °CPhysProp
logP2.82HANSCH,C ET AL. (1995)
pKa5MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.03 mg/mLALOGPS
logP3.36ALOGPS
logP3.13ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)10.85ChemAxon
pKa (Strongest Basic)8.66ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area171.17 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity221.48 m3·mol-1ChemAxon
Polarizability88.59 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9738
Blood Brain Barrier-0.9514
Caco-2 permeable+0.6262
P-glycoprotein substrateSubstrate0.9027
P-glycoprotein inhibitor IInhibitor0.6573
P-glycoprotein inhibitor IIInhibitor0.6919
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8071
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7666
CYP450 1A2 substrateNon-inhibitor0.9203
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.7491
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8574
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8938
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9324 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9699
hERG inhibition (predictor II)Inhibitor0.5265
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Vinca alkaloids
Sub Class
Not Available
Direct Parent
Vinca alkaloids
Alternative Parents
Carbazoles / 3-alkylindoles / Tricarboxylic acids and derivatives / Anisoles / Alkyl aryl ethers / Aralkylamines / Piperidines / N-alkylpyrrolidines / Methyl esters / Heteroaromatic compounds
show 12 more
Substituents
Vinca alkaloid skeleton / Carbazole / 3-alkylindole / Indole / Indole or derivatives / Tricarboxylic acid or derivatives / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary alcohol, tertiary amino compound, organic heterotetracyclic compound, organic heteropentacyclic compound, formamides, acetate ester, methyl ester, vinca alkaloid (CHEBI:28445) / Indole alkaloids (C07204)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ubiquitin protein ligase binding
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name
TUBB
Uniprot ID
P07437
Uniprot Name
Tubulin beta chain
Molecular Weight
49670.515 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, Krumbholz RD, Schmid SM, Teicher BA: Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemother Pharmacol. 2009 Oct;64(5):1029-38. doi: 10.1007/s00280-009-0959-z. Epub 2009 Mar 10. [PubMed:19277662]
  4. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M: Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub 2010 May 4. [PubMed:20442307]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Structural constituent of cytoskeleton
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name
TUBA4A
Uniprot ID
P68366
Uniprot Name
Tubulin alpha-4A chain
Molecular Weight
49923.995 Da
References
  1. Yasui M, Koyama N, Koizumi T, Senda-Murata K, Takashima Y, Hayashi M, Sugimoto K, Honma M: Live cell imaging of micronucleus formation and development. Mutat Res. 2010 Oct 13;692(1-2):12-8. doi: 10.1016/j.mrfmmm.2010.07.009. Epub 2010 Aug 5. [PubMed:20691709]
  2. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M: Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub 2010 May 4. [PubMed:20442307]
  3. Vilpo JA, Koski T, Vilpo LM: Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol. 2000 Dec;65(6):370-8. [PubMed:11168494]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Arora A, Shukla Y: Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett. 2003 Jan 28;189(2):167-73. [PubMed:12490309]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  3. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945]
  4. Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H: Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999 Jan;288(1):348-57. [PubMed:9862789]
  5. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  6. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535]
  7. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675]
  8. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004 Jul 1;64(13):4621-8. [PubMed:15231674]
  9. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4. [PubMed:19123050]
  10. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995]
  11. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009 Feb 15;69(4):1494-501. doi: 10.1158/0008-5472.CAN-08-2483. Epub 2009 Feb 3. [PubMed:19190342]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Loe DW, Almquist KC, Cole SP, Deeley RG: ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem. 1996 Apr 19;271(16):9683-9. [PubMed:8621644]
  2. Godinot N, Iversen PW, Tabas L, Xia X, Williams DC, Dantzig AH, Perry WL 3rd: Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey. Mol Cancer Ther. 2003 Mar;2(3):307-16. [PubMed:12657726]
  3. Nunoya K, Grant CE, Zhang D, Cole SP, Deeley RG: Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26. [PubMed:12867490]
  4. Sumizawa T, Chen ZS, Chuman Y, Seto K, Furukawa T, Haraguchi M, Tani A, Shudo N, Akiyama SI: Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol. 1997 Mar;51(3):399-405. [PubMed:9058594]
  5. Renes J, de Vries EG, Nienhuis EF, Jansen PL, Muller M: ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol. 1999 Feb;126(3):681-8. [PubMed:10188979]
  6. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SP, Deeley RG: Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53. [PubMed:9281595]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806]
  2. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674]
  3. Ishikawa T, Muller M, Klunemann C, Schaub T, Keppler D: ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem. 1990 Nov 5;265(31):19279-86. [PubMed:2172249]
  4. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219-28. [PubMed:10570049]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44. [PubMed:12649196]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transmembrane transporter activity
Specific Function
Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the ma...
Gene Name
RALBP1
Uniprot ID
Q15311
Uniprot Name
RalA-binding protein 1
Molecular Weight
76062.86 Da
References
  1. Drake KJ, Singhal J, Yadav S, Nadkar A, Pungaliya C, Singhal SS, Awasthi S: RALBP1/RLIP76 mediates multidrug resistance. Int J Oncol. 2007 Jan;30(1):139-44. [PubMed:17143522]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:23